Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 101 entries
Sorted by: Best Match Show Resources per page
Urinary polycyclic aromatic hydrocarbons in relation to anthropometric measures and pubertal development in a cohort of Northern California girls.

Environmental epidemiology (Philadelphia, Pa.)

Dobraca D, Laurent CA, Greenspan LC, Hiatt RA, Sjödin A, Kushi LH, Windham GC.
PMID: 32832841
Environ Epidemiol. 2020 Jul 06;4(4):e0102. doi: 10.1097/EE9.0000000000000102. eCollection 2020 Aug.

BACKGROUND: Polycyclic aromatic hydrocarbons (PAHs) are a class of ubiquitous, environmental chemicals that may have endocrine disrupting capabilities. We investigated whether childhood exposure to PAHs was associated with adiposity and pubertal timing in a longitudinal study of 404 girls...

Cite
Dobraca D, Laurent CA, Greenspan LC, et al. Urinary polycyclic aromatic hydrocarbons in relation to anthropometric measures and pubertal development in a cohort of Northern California girls. Environ Epidemiol. 2020;4(4):e0102doi: 10.1097/EE9.0000000000000102.
Dobraca, D., Laurent, C. A., Greenspan, L. C., Hiatt, R. A., Sjödin, A., Kushi, L. H., & Windham, G. C. (2020). Urinary polycyclic aromatic hydrocarbons in relation to anthropometric measures and pubertal development in a cohort of Northern California girls. Environmental epidemiology (Philadelphia, Pa.), 4(4), e0102. https://doi.org/10.1097/EE9.0000000000000102
Dobraca, Dina, et al. "Urinary polycyclic aromatic hydrocarbons in relation to anthropometric measures and pubertal development in a cohort of Northern California girls." Environmental epidemiology (Philadelphia, Pa.) vol. 4,4 (2020): e0102. doi: https://doi.org/10.1097/EE9.0000000000000102
Dobraca D, Laurent CA, Greenspan LC, Hiatt RA, Sjödin A, Kushi LH, Windham GC. Urinary polycyclic aromatic hydrocarbons in relation to anthropometric measures and pubertal development in a cohort of Northern California girls. Environ Epidemiol. 2020 Jul 06;4(4):e0102. doi: 10.1097/EE9.0000000000000102. eCollection 2020 Aug. PMID: 32832841; PMCID: PMC7423521.
Copy Download .nbib Format: NLM
The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R.

Seminars in oncology

Wilson WH, Gutierrez M, O'Connor P, Frankel S, Jaffe E, Chabner BA, Grossbard ML.
PMID: 28140091
Semin Oncol. 2002 Feb;29(1):41-47. doi: 10.1053/sonc.2002.30151.

Accumulating evidence suggests that the ability to activate apoptotic pathways may be an important determinant of chemotherapy sensitivity and presents a potentially important new therapeutic strategy. Monoclonal antibodies against the CD20 antigen directly induce apoptosis and may serve to...

Cite
Wilson WH, Gutierrez M, O'Connor P, et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R. Semin Oncol. 2002;29(1):41-47doi: 10.1053/sonc.2002.30151.
Wilson, W. H., Gutierrez, M., O'Connor, P., Frankel, S., Jaffe, E., Chabner, B. A., & Grossbard, M. L. (2002). The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R. Seminars in oncology, 29(1), 41-47. https://doi.org/10.1053/sonc.2002.30151
Wilson, Wyndham H, et al. "The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R." Seminars in oncology vol. 29,1 (2002): 41-47. doi: https://doi.org/10.1053/sonc.2002.30151
Wilson WH, Gutierrez M, O'Connor P, Frankel S, Jaffe E, Chabner BA, Grossbard ML. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R. Semin Oncol. 2002 Feb;29(1):41-47. doi: 10.1053/sonc.2002.30151. PMID: 28140091.
Copy Download .nbib Format: NLM
Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma.

Hepatology communications

Ben-Yakov G, Alao H, Haydek JP, Fryzek N, Cho MH, Hemmati M, Samala V, Shovlin M, Dunleavy K, Wilson W, Jones EC, Rotman Y.
PMID: 30766960
Hepatol Commun. 2018 Dec 28;3(2):220-226. doi: 10.1002/hep4.1304. eCollection 2019 Feb.

Nonalcoholic fatty liver disease is the most common liver disorder in the developed world. Although typically reflecting caloric overload, it can also be secondary to drug toxicity. We aimed to describe the incidence and risk factors for

Cite
Ben-Yakov G, Alao H, Haydek JP, et al. Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma. Hepatol Commun. 2018;3(2):220-226doi: 10.1002/hep4.1304.
Ben-Yakov, G., Alao, H., Haydek, J. P., Fryzek, N., Cho, M. H., Hemmati, M., Samala, V., Shovlin, M., Dunleavy, K., Wilson, W., Jones, E. C., & Rotman, Y. (2019). Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma. Hepatology communications, 3(2), 220-226. https://doi.org/10.1002/hep4.1304
Ben-Yakov, Gil, et al. "Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma." Hepatology communications vol. 3,2 (2019): 220-226. doi: https://doi.org/10.1002/hep4.1304
Ben-Yakov G, Alao H, Haydek JP, Fryzek N, Cho MH, Hemmati M, Samala V, Shovlin M, Dunleavy K, Wilson W, Jones EC, Rotman Y. Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma. Hepatol Commun. 2018 Dec 28;3(2):220-226. doi: 10.1002/hep4.1304. eCollection 2019 Feb. PMID: 30766960; PMCID: PMC6357828.
Copy Download .nbib Format: NLM
Reduction of biliverdin to bilirubin in tissues.

The Biochemical journal

Lemberg R, Wyndham RA.
PMID: 16746138
Biochem J. 1936 Jul;30(7):1147-70. doi: 10.1042/bj0301147.

No abstract available.

Cite
Lemberg R, Wyndham RA. Reduction of biliverdin to bilirubin in tissues. Biochem J. 1936;30(7):1147-70doi: 10.1042/bj0301147.
Lemberg, R., & Wyndham, R. A. (1936). Reduction of biliverdin to bilirubin in tissues. The Biochemical journal, 30(7), 1147-70. https://doi.org/10.1042/bj0301147
Lemberg, R, and Wyndham, R A. "Reduction of biliverdin to bilirubin in tissues." The Biochemical journal vol. 30,7 (1936): 1147-70. doi: https://doi.org/10.1042/bj0301147
Lemberg R, Wyndham RA. Reduction of biliverdin to bilirubin in tissues. Biochem J. 1936 Jul;30(7):1147-70. doi: 10.1042/bj0301147. PMID: 16746138; PMCID: PMC1263160.
Copy Download .nbib Format: NLM
Current measurement by Faraday effect on GEPOPU.

Applied optics

Correa N, Chuaqui H, Wyndham E, Veloso F, Valenzuela J, Favre M, Bhuyan H.
PMID: 22358166
Appl Opt. 2012 Feb 20;51(6):758-62. doi: 10.1364/AO.51.000758.

The design of an optical current sensor to be used in a pulsed power generator is presented. The current sensor is based on the polarization rotation by the Faraday effect. GEPOPU is a pulsed power generator, 110 kA, 120...

Cite
Correa N, Chuaqui H, Wyndham E, et al. Current measurement by Faraday effect on GEPOPU. Appl Opt. 2012;51(6):758-62doi: 10.1364/AO.51.000758.
Correa, N., Chuaqui, H., Wyndham, E., Veloso, F., Valenzuela, J., Favre, M., & Bhuyan, H. (2012). Current measurement by Faraday effect on GEPOPU. Applied optics, 51(6), 758-62. https://doi.org/10.1364/AO.51.000758
Correa, Noemí, et al. "Current measurement by Faraday effect on GEPOPU." Applied optics vol. 51,6 (2012): 758-62. doi: https://doi.org/10.1364/AO.51.000758
Correa N, Chuaqui H, Wyndham E, Veloso F, Valenzuela J, Favre M, Bhuyan H. Current measurement by Faraday effect on GEPOPU. Appl Opt. 2012 Feb 20;51(6):758-62. doi: 10.1364/AO.51.000758. PMID: 22358166.
Copy Download .nbib Format: NLM
Simple holographic polarogram.

Applied optics

Inestrosa MJ, Chuaqui H, Aliaga-Rossel R, Favre M, Mitchell I, Wyndham E.
PMID: 18311258
Appl Opt. 2008 Mar 01;47(7):883-7. doi: 10.1364/ao.47.000883.

A new technique capable of obtaining quantitative values of the rotation angle of the polarization vector by using holography is presented. This is a two-stage holographic process; during the recording stage a hologram of the object of interest is...

Cite
Inestrosa MJ, Chuaqui H, Aliaga-Rossel R, et al. Simple holographic polarogram. Appl Opt. 2008;47(7):883-7doi: 10.1364/ao.47.000883.
Inestrosa, M. J., Chuaqui, H., Aliaga-Rossel, R., Favre, M., Mitchell, I., & Wyndham, E. (2008). Simple holographic polarogram. Applied optics, 47(7), 883-7. https://doi.org/10.1364/ao.47.000883
Inestrosa, Maria José, et al. "Simple holographic polarogram." Applied optics vol. 47,7 (2008): 883-7. doi: https://doi.org/10.1364/ao.47.000883
Inestrosa MJ, Chuaqui H, Aliaga-Rossel R, Favre M, Mitchell I, Wyndham E. Simple holographic polarogram. Appl Opt. 2008 Mar 01;47(7):883-7. doi: 10.1364/ao.47.000883. PMID: 18311258.
Copy Download .nbib Format: NLM
In vitro microbial degradation of bituminous hydrocarbons and in situ colonization of bitumen surfaces within the athabasca oil sands deposit.

Applied and environmental microbiology

Wyndham RC, Costerton JW.
PMID: 16345738
Appl Environ Microbiol. 1981 Mar;41(3):791-800. doi: 10.1128/aem.41.3.791-800.1981.

Bituminous hydrocarbons extracted from the Athabasca oil sands of north-eastern Alberta were adsorbed onto filter supports and placed at sites in the Athabasca River and its tributaries where these rivers come in contact with the oil sands formation. Colonization...

Cite
Wyndham RC, Costerton JW. In vitro microbial degradation of bituminous hydrocarbons and in situ colonization of bitumen surfaces within the athabasca oil sands deposit. Appl Environ Microbiol. 1981;41(3):791-800doi: 10.1128/aem.41.3.791-800.1981.
Wyndham, R. C., & Costerton, J. W. (1981). In vitro microbial degradation of bituminous hydrocarbons and in situ colonization of bitumen surfaces within the athabasca oil sands deposit. Applied and environmental microbiology, 41(3), 791-800. https://doi.org/10.1128/aem.41.3.791-800.1981
Wyndham, R C, and Costerton, J W. "In vitro microbial degradation of bituminous hydrocarbons and in situ colonization of bitumen surfaces within the athabasca oil sands deposit." Applied and environmental microbiology vol. 41,3 (1981): 791-800. doi: https://doi.org/10.1128/aem.41.3.791-800.1981
Wyndham RC, Costerton JW. In vitro microbial degradation of bituminous hydrocarbons and in situ colonization of bitumen surfaces within the athabasca oil sands deposit. Appl Environ Microbiol. 1981 Mar;41(3):791-800. doi: 10.1128/aem.41.3.791-800.1981. PMID: 16345738; PMCID: PMC243776.
Copy Download .nbib Format: NLM
Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972-1980.

Diabetes care

Aroda VR, Rosenstock J, Wysham C, Unger J, Bellido D, González-Gálvez G, Takami A, Guo H, Niemoeller E, Souhami E, Bergenstal RM.
PMID: 28428368
Diabetes Care. 2017 Jun;40(6):809. doi: 10.2337/dc17-er06d. Epub 2017 Apr 20.

No abstract available.

Cite
Aroda VR, Rosenstock J, Wysham C, et al. Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972-1980. Diabetes Care. 2017;40(6):809doi: 10.2337/dc17-er06d.
Aroda, V. R., Rosenstock, J., Wysham, C., Unger, J., Bellido, D., González-Gálvez, G., Takami, A., Guo, H., Niemoeller, E., Souhami, E., Bergenstal, R. M. (2017). Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972-1980. Diabetes care, 40(6), 809. https://doi.org/10.2337/dc17-er06d
Aroda, Vanita R, et al. "Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972-1980." Diabetes care vol. 40,6 (2017): 809. doi: https://doi.org/10.2337/dc17-er06d
Aroda VR, Rosenstock J, Wysham C, Unger J, Bellido D, González-Gálvez G, Takami A, Guo H, Niemoeller E, Souhami E, Bergenstal RM. Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972-1980. Diabetes Care. 2017 Jun;40(6):809. doi: 10.2337/dc17-er06d. Epub 2017 Apr 20. PMID: 28428368; PMCID: PMC5439418.
Copy Download .nbib Format: NLM
Chromatographic evidence of silyl ether formation (SEF) in supercritical fluid chromatography.

Analytical chemistry

Fairchild JN, Brousmiche DW, Hill JF, Morris MF, Boissel CA, Wyndham KD.
PMID: 25514458
Anal Chem. 2015 Feb 03;87(3):1735-42. doi: 10.1021/ac5035709. Epub 2015 Jan 09.

In this article, we propose that silyl ether formation (SEF) is a major contribution to retention and selectivity variation over time for supercritical fluid chromatography (SFC). In the past, the variations were attributed to instrumentation, but high performance SFC...

Cite
Fairchild JN, Brousmiche DW, Hill JF, et al. Chromatographic evidence of silyl ether formation (SEF) in supercritical fluid chromatography. Anal Chem. 2015;87(3):1735-42doi: 10.1021/ac5035709.
Fairchild, J. N., Brousmiche, D. W., Hill, J. F., Morris, M. F., Boissel, C. A., & Wyndham, K. D. (2015). Chromatographic evidence of silyl ether formation (SEF) in supercritical fluid chromatography. Analytical chemistry, 87(3), 1735-42. https://doi.org/10.1021/ac5035709
Fairchild, Jacob N, et al. "Chromatographic evidence of silyl ether formation (SEF) in supercritical fluid chromatography." Analytical chemistry vol. 87,3 (2015): 1735-42. doi: https://doi.org/10.1021/ac5035709
Fairchild JN, Brousmiche DW, Hill JF, Morris MF, Boissel CA, Wyndham KD. Chromatographic evidence of silyl ether formation (SEF) in supercritical fluid chromatography. Anal Chem. 2015 Feb 03;87(3):1735-42. doi: 10.1021/ac5035709. Epub 2015 Jan 09. PMID: 25514458.
Copy Download .nbib Format: NLM
Recognizing Indigenous peoples' and local communities' rights and agency in the post-2020 Biodiversity Agenda.

Ambio

Reyes-García V, Fernández-Llamazares Á, Aumeeruddy-Thomas Y, Benyei P, Bussmann RW, Diamond SK, García-Del-Amo D, Guadilla-Sáez S, Hanazaki N, Kosoy N, Lavides M, Luz AC, McElwee P, Meretsky VJ, Newberry T, Molnár Z, Ruiz-Mallén I, Salpeteur M, Wyndham FS, Zorondo-Rodriguez F, Brondizio ES.
PMID: 34008095
Ambio. 2022 Jan;51(1):84-92. doi: 10.1007/s13280-021-01561-7. Epub 2021 May 18.

The Convention on Biological Diversity is defining the goals that will frame future global biodiversity policy in a context of rapid biodiversity decline and under pressure to make transformative change. Drawing on the work of Indigenous and non-Indigenous scholars,...

Cite
Reyes-García V, Fernández-Llamazares Á, Aumeeruddy-Thomas Y, et al. Recognizing Indigenous peoples' and local communities' rights and agency in the post-2020 Biodiversity Agenda. Ambio. 2021;51(1):84-92doi: 10.1007/s13280-021-01561-7.
Reyes-García, V., Fernández-Llamazares, �. �., Aumeeruddy-Thomas, Y., Benyei, P., Bussmann, R. W., Diamond, S. K., García-Del-Amo, D., Guadilla-Sáez, S., Hanazaki, N., Kosoy, N., Lavides, M., Luz, A. C., McElwee, P., Meretsky, V. J., Newberry, T., Molnár, Z., Ruiz-Mallén, I., Salpeteur, M., Wyndham, F. S., Zorondo-Rodriguez, F., & Brondizio, E. S. (2022). Recognizing Indigenous peoples' and local communities' rights and agency in the post-2020 Biodiversity Agenda. Ambio, 51(1), 84-92. https://doi.org/10.1007/s13280-021-01561-7
Reyes-García, Victoria, et al. "Recognizing Indigenous peoples' and local communities' rights and agency in the post-2020 Biodiversity Agenda." Ambio vol. 51,1 (2022): 84-92. doi: https://doi.org/10.1007/s13280-021-01561-7
Reyes-García V, Fernández-Llamazares Á, Aumeeruddy-Thomas Y, Benyei P, Bussmann RW, Diamond SK, García-Del-Amo D, Guadilla-Sáez S, Hanazaki N, Kosoy N, Lavides M, Luz AC, McElwee P, Meretsky VJ, Newberry T, Molnár Z, Ruiz-Mallén I, Salpeteur M, Wyndham FS, Zorondo-Rodriguez F, Brondizio ES. Recognizing Indigenous peoples' and local communities' rights and agency in the post-2020 Biodiversity Agenda. Ambio. 2022 Jan;51(1):84-92. doi: 10.1007/s13280-021-01561-7. Epub 2021 May 18. PMID: 34008095.
Copy Download .nbib Format: NLM
Preparing for the next pandemic.

BMJ (Clinical research ed.)

Wenham C, Kavanagh M, Torres I, Yamey G.
PMID: 34020969
BMJ. 2021 May 21;373:n1295. doi: 10.1136/bmj.n1295.

No abstract available.

Cite
Wenham C, Kavanagh M, Torres I, et al. Preparing for the next pandemic. BMJ. 2021;373:n1295doi: 10.1136/bmj.n1295.
Wenham, C., Kavanagh, M., Torres, I., & Yamey, G. (2021). Preparing for the next pandemic. BMJ (Clinical research ed.), 373n1295. https://doi.org/10.1136/bmj.n1295
Wenham, Clare, et al. "Preparing for the next pandemic." BMJ (Clinical research ed.) vol. 373 (2021): n1295. doi: https://doi.org/10.1136/bmj.n1295
Wenham C, Kavanagh M, Torres I, Yamey G. Preparing for the next pandemic. BMJ. 2021 May 21;373:n1295. doi: 10.1136/bmj.n1295. PMID: 34020969.
Copy Download .nbib Format: NLM
Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting.

Clinical cancer research : an official journal of the American Association for Cancer Research

Morris JS, Luthra R, Liu Y, Duose DY, Lee W, Reddy NG, Windham J, Chen H, Tong Z, Zhang B, Wei W, Ganiraju M, Broom BM, Alvarez HA, Mejia A, Veeranki O, Routbort MJ, Morris VK, Overman MJ, Menter D, Katkhuda R, Wistuba II, Davis JS, Kopetz S, Maru DM.
PMID: 33109741
Clin Cancer Res. 2021 Jan 01;27(1):120-130. doi: 10.1158/1078-0432.CCR-20-2403. Epub 2020 Oct 27.

PURPOSE: Consensus molecular subtyping (CMS) of colorectal cancer has potential to reshape the colorectal cancer landscape. We developed and validated an assay that is applicable on formalin-fixed, paraffin-embedded (FFPE) samples of colorectal cancer and implemented the assay in a...

Cite
Morris JS, Luthra R, Liu Y, et al. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res. 2020;27(1):120-130doi: 10.1158/1078-0432.CCR-20-2403.
Morris, J. S., Luthra, R., Liu, Y., Duose, D. Y., Lee, W., Reddy, N. G., Windham, J., Chen, H., Tong, Z., Zhang, B., Wei, W., Ganiraju, M., Broom, B. M., Alvarez, H. A., Mejia, A., Veeranki, O., Routbort, M. J., Morris, V. K., Overman, M. J., Menter, D., Katkhuda, R., Wistuba, I. I., Davis, J. S., Kopetz, S., & Maru, D. M. (2021). Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(1), 120-130. https://doi.org/10.1158/1078-0432.CCR-20-2403
Morris, Jeffrey S, et al. "Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,1 (2021): 120-130. doi: https://doi.org/10.1158/1078-0432.CCR-20-2403
Morris JS, Luthra R, Liu Y, Duose DY, Lee W, Reddy NG, Windham J, Chen H, Tong Z, Zhang B, Wei W, Ganiraju M, Broom BM, Alvarez HA, Mejia A, Veeranki O, Routbort MJ, Morris VK, Overman MJ, Menter D, Katkhuda R, Wistuba II, Davis JS, Kopetz S, Maru DM. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res. 2021 Jan 01;27(1):120-130. doi: 10.1158/1078-0432.CCR-20-2403. Epub 2020 Oct 27. PMID: 33109741; PMCID: PMC8713413.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 101 entries